HERSTATIN: A NOVEL CANCER THERAPEUTIC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目的主要目标是表征一种新的HER-2原癌基因亚型的表达和作用。这种被称为Herstatin的异构体是内含子保留和含有唯一内含子编码的C末端的HER-2的截短版本合成的结果。该奖项支持的研究包括使用Transwell共培养评估前列腺癌和乳腺癌细胞株的体外表达和抑制生长，以及调查全长蛋白质的C末端片段的活性。最近，我们利用质粒载体和慢病毒方法研究了多个细胞系中Herstatin的分泌，并使用了异源信号序列来促进分泌。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project has as its principal goal the characterization of the expression and action of a novel isoform of the Her-2 protooncogene. This isoform, termed herstatin, results from intron retention and the synthesis of a truncated version of Her-2 containing a unique intron-encoded C terminus. The studies supported by this award include assessment of expression and inhibition of growth of prostate and breast cancer cell lines in vitro using transwell co-culture as well as investigation of the activity of C-terminal fragments of the full-length protein. We have most recently investigated the secretion of herstatin from multiple cell lines using both plasmid vector and lentivirus approaches and have employed heterologous signal sequences to enhance secretion.